Bristol-Myers Squibb Company
TGF beta receptor antagonists
Last updated:
Abstract:
The invention relates generally to compounds that modulate the activity of TGF.beta.R-1 and TGF.beta.R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
27 Jul 2016
Issue date:
3 Sep 2019